Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Suicidal Ideation MRI Study
NCT02532153Phase 3Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2017
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ketamine in suicidal ideation, sponsored by Massachusetts General Hospital. Planned start Feb 2017; status: withdrawn.
02
Drugs
ketamine
03
Conditions
suicidal ideation
Beyond the preview
Go deeper on NCT02532153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532153.